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Summary 
Background and purpose: the aim of this study was to quantify and characterise the 
mechanism of non-neuronal acetylcholine (ACh) release from bladder urothelial cells 
and to determine if urothelial cells could be a site of action of anti-muscarinic drugs. 
Experimental approach: a novel technique was developed whereby ACh could be 
measured from freshly isolated guinea-pig urothelial cells in suspension following 
mechanical stimulation. Various agents were used to manipulate possible ACh-release 
pathways in turn and to study the effects of muscarinic receptor activation and 
inhibition on urothelial ATP release.  
Key results: minimal mechanical stimulus achieved full ACh release, indicating a 
small dynamic range and possible all-or-none signal. ACh release involved a 
mechanism dependent on CFTR and intracellular calcium concentration, but was 
independent of extracellular calcium, vesicular trafficking, connexins or pannexins, 
organic cation transporters and was not affected by botulinum-A toxin. Stimulating 
ACh receptors increased ATP production and antagonising them reduced ATP release, 
suggesting a link between ACh and ATP release.    
Conclusions and implications: These results suggest that non-neuronal ACh release 
from the urothelium is large enough and well located to act as a modulator of ATP 
release. It is hypothesised that this pathway may contribute to the actions of 
antimuscarinic drugs in reducing the symptoms of lower urinary tract syndromes. 
Additionally an involvement of CFTR in ACh release suggests an exciting new 
direction for the treatment of these conditions. 
Key Words: Non-neuronal acetylcholine (ACh), urothelial cells, ATP, anti-muscarinic 
agents, CFTR, urinary bladder.  
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Introduction  
The bladder urothelium is exquisitely designed to provide a barrier to the urine 
contained within the bladder whilst also being a sensory epithelium both releasing and 
responding to numerous chemical transmitters. There is now good evidence that 
acetylcholine (ACh) is one of these transmitters, as the urothelium has been shown to 
contain all the enzymes required to synthesise ACh (Hanna-Mitchell et al., 2007; Lips 
et al., 2007; Yoshida et al., 2006), non-neuronal ACh release is reduced following 
urothelium removal (Yoshida et al., 2006; Yoshida et al., 2004) and cultured urothelial 
cells have been demonstrated to release ACh (Hanna-Mitchell et al., 2007). This non-
neuronal ACh release only accounts for about 1-2% of the total bladder ACh in people 
below 65, but rises to 5% or more with age (Yoshida et al., 2004). Given its small 
contribution, the role of non-neuronal ACh is unclear but it may regulate bladder tone 
and contribute to overactive bladder contractions, because antimuscarinic drugs are 
most effective during the storage phase when neuronal release is low (Andersson, 2011; 
Yoshida et al., 2004). An autocrine signalling role is also possible, regulating its own 
release (Hanna-Mitchell et al., 2007) or that of other mediators such as ATP or nitric 
oxide. Functional muscarinic and nicotinic receptors have been demonstrated in 
cultured urothelial cells and a link to ATP release demonstrated in guinea-pig bladder 
strips (Beckel et al., 2006; Hanna-Mitchell et al., 2007; Kullmann et al., 2008; Young 
et al., 2012).  
The mechanism of urothelial cell ACh release is unknown, although it is probably non-
vesicular as it is insensitive to brefeldin-A and also urothelial cells lack a vesicular ACh 
transporter (Hanna-Mitchell et al., 2007). In human placenta, organic cation 
transporters OCT1 and OCT3 are implicated in ACh release as OCT1 transported ACh 
when expressed in Xenopus oocytes (Lips et al., 2005; Wessler et al., 2001). Both 
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OCT1 and OCT3 are present in mouse and human urothelium, although neither has 
been demonstrated to be involved in ACh release in bladder (Lips et al., 2007). 
Here, we used freshly isolated guinea-pig urothelial cells to characterise the mechanism 
of ACh release. Using freshly isolated rather than cultured cells allowed less time for 
morphological (Woodman et al., 2011) and functional changes and also reduced the 
possibility of contamination from faster growing non-urothelial cells, whilst still 
utilising an almost pure population of known cellular composition, not possible with 
whole tissue. We used a range of agents to investigate possible ACh release pathways 
and also investigated the effects of ACh on ATP release from urothelial cells.  
The results presented here show that ACh is released from urothelial cells when 
mechanically stimulated by a novel route that differs from that of ATP. It is 
hypothesised that this ACh controls ATP release and that this pathway may contribute 
to the actions of antimuscarinic agents in reducing symptoms of lower urinary tract 
syndrome and painful bladder syndrome.  Preliminary findings were presented to the 
International Continence Society  (Fry et al., 2013). 
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Materials and Methods 
Cell isolation.  Male guinea-pigs (Dunkin-Hartley; 400-600g) were euthanized by 
cervical dislocation (according to UK Animals, Scientific Procedures Act 1986 and 
European Communities Council Directive 86/09/EEC and approved by the ethical 
committee of Faculty of Health and Medical Sciences, University of Surrey). Bladders 
were immediately excised, the mucosa removed by blunt dissection and incubated at 
37°C with trypsin-EDTA (0.5 g/l trypsin, 0.2 g/l EDTA Sigma) in PBS for 
approximately 40 minutes. Urothelial cells were released by gentle titration, washed 
with Tyrode’s solution, a sample taken and counted and the cell suspension incubated in 
Eppendorf tubes at a known density. By varying the length of incubation with trypsin-
EDTA it was possible to obtain a population containing varying percentages of the three 
subtypes of urothelial cells; shorter incubation having more of the larger cells for 
example. For the study shown in Figure 3C two extreme populations were obtained, 
with a high and a low percentage of the larger umbrella cells. These were then diluted to 
give the same number of these types of cells per ml, but obviously with a different total 
cell density and then mixed in different ratios to give the intermediate densities. 
 
When used, one of brefeldin-A (10
-5 
g/ml), CFTRinh-172 (3x10
-8– 7.5 x 10-5 M), quinine 
(10
-4 
M), botulinum toxin-A (4U & 10U) was added at this stage. Carbachol (10
-5 
M) 
and 4-DAMP (5 x 10
-7 
M) were added just prior to measurement of transmitter release 
and carbenoxolone (5x10
-4 
M), 35-50 minutes before testing. Methoctramine was either 
added at the start of incubation (for experiments with carbachol as well) or just prior to 
measuring transmitter release for the other experiments (10
-8
-10
-5 
M). Appropriate 
vehicle/dilution controls were used in all cases. All experiments were done at room 
temperature. 
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Cell counting.  All cell counts used an improved Neubauer haemocytometer stage.  The 
percentage of viable cells was calculated by the proportion excluding Trypan Blue (0.4 
% solution) added to a 10 μl sample of the cell suspension. All cell preparations were 
counted and the percentage excluding trypan blue measured from a sample taken before 
using the rest of the population. The percentage of large, medium and small sized cells 
was estimated visually from two separate counts of each population. In five 
preparations cell diameter, x, was measured and plotted as a histogram in 1 μm bins.  
Each histogram was positively skewed and optimal fits were obtained by fitting them to 
three Gaussian distributions (equation 1), i.e. the variance of the fit was significantly 
reduced with three distributions using Fisher’s exact test. 
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                           1 
Where n=number of cells,   
  
x  and s are the mean and standard deviation of an individual 
distribution.  Histograms were initially fitted to the smallest bin sizes (8-12 μm) to 
generate the first distribution and the residuals treated in a similar way to generate 
distributions for intermediate and the largest cell populations. Total cell number and the 
proportion in each population were calculated for each cell preparation. 
 
Immunohistochemistry.  Epitope labelling on cells was done at room temperature. 
Suspensions were fixed with 2% paraformaldehyde for six minutes and then washed 
twice in phosphate-buffered saline (PBS; 40 g, six minutes each time).  PBS with 1% 
BSA and 0.2% triton was added for at least an hour followed by primary antibody, 
Anti-KRT20 at 1:100 (Sigma WH0054474M1, mouse monoclonal) for one hour. 
Following washing, secondary antibody (Alexa-Fluor 488 goat anti-mouse, Invitrogen A
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A10680 at 1:500) was added for 45 minutes and the cells washed and viewed using 
confocal microscopy.  
 
CFTR immunohistochemistry used the same protocol except that 12 μm sections of 
whole bladder were used, paraformaldehyde was only applied for four minutes, 0.5% 
triton and 3% BSA were used and incubation with primary antibody was 24 hours at 
4
o
C (Abcam anti-CFTR ab2784, mouse monoclonal, 1:50). Vectashield (Vector labs) 
was used to mount sections before viewing.  
 
ACh and ATP stimulation and measurement.  Cell suspensions (45 μl samples) were 
stabilised in Tyrode’s solution (below) for at least 90 minutes, after which a mechanical 
shear stress was applied by pipetting 20 μl of suspension up and down at a constant 
speed, using the same pipette and type of pipette tip (see Appendix for more details). 
ACh was measured, using an Amplex®Red ACh/acetyl cholinesterase assay kit 
(Invitrogen, A12217), from 20 μl samples taken immediately following five such 
actions (except Figure 2A) and rapidly frozen until required. These samples were then 
mixed with 20μl of the reaction mixture made as given in the instructions for the kit 
except for the smaller volume used. Fluorescence was measured at 590 nm following 
excitation at 544 nm using a BMG FLUOstar Omega multi-mode plate reader. ACh 
standards were included in all plates (3x10
-8–3x10-4 M) and fluorescence increase with 
concentration as shown in Figure 2A. Stimulated ATP release was measured four 
minutes after shear stress (one minute for Figure 2B) using a luciferin-luciferase assay 
(FL-AAM, Sigma, GloMax 20/20; Promega) with either a one in two or a one in ten 
dilution. Four minutes was used as the ATP level was found to be stable over this 
period and it was more convenient and allowed tubes from different treatment groups to 
be processed in parallel. Luminescence was a linear function of concentration on a 
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calibration log-log plot over the range 1x10
-10–10-6 M. The different number of 
pipetting stimuli of five and fifty stimuli for ACh and ATP respectively were each 
chosen to be maximal (see Figures 2C and 2D) to minimise the effects of any small 
variations in the speed or strength of the stimulation. In all experiments multiple tubes 
were used for each treatment and averaged to give a single n value to reduce variability 
from errors in stimulus reproducibility still further. The use of multiple tubes for each 
treatment should also have randomised any errors in stimulus reproducibility between 
groups and thereby would not be expected to have been responsible for any of the 
differences seen between groups. Five pipetting stimuli had no significant effect on cell 
viability as Trypan blue exclusion was not significantly changed as compared to 
controls (89.3±1.4% compared to control of 88.6±1.8%, n=5). Fifty stimuli did cause a 
small increase in Trypan blue uptake but his would have been common to both test and 
control groups and was therefore unlikely to have caused the differences seen (81.6% as 
compared to control of 86.1% cells excluded Trypan blue, n=8). 
 
 
Solutions.  Tyrode’s solution (mM: NaCl 118, NaHCO3 24, KCl 4.0, MgCl2 1.0, 
NaH2PO4 0.4, glucose 6.1, sodium pyruvate 5.0, gassed with 95% O2/5% CO2) with no 
added calcium was used for all experiments except Figure 3D where either 1.8 mM 
CaCl2 was added as indicated, or low sodium solution was used. Low sodium solution 
was made as for Tyrode’s solution but with Tris substituted for NaCl. This solution had 
a calculated sodium concentration of 29 mM instead of 147.4 mM. During cell isolation 
PBS and trypsin-EDTA were used.  All chemicals were from Sigma, UK.  
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Statistics and curve-fitting.  Mean ACh/ATP release values, when normalised to cell 
surface area, were not indistinguishable from a normal distribution by a Kolmogorov-
Smirnov test.  Data are therefore expressed as mean values ± SEM.  ATP or ACh 
release in the presence of an agent is expressed as a percentage of its paired vehicle 
control. A paired Student’s t-test was used to compare ACh or ATP release in the 
presence of each agent with it’s time matched vehicle control: the null hypothesis was 
rejected at p<0.05.  In all experiments n number indicates the number of animals except 
those in Figures 3A & B where separate populations with different distributions of the 
three sub-types of cells or a different total density were included from the same animal. 
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Results  
Urothelial cell characterisation: The isolated guinea-pig urothelial cells (Figure 1A) 
ranged in diameter from 7-40 μm and had a frequency size distribution that was well-
fitted by three Gaussian distributions (Figure 1B) called in ascending size basal, 
intermediate and umbrella populations. From five sample preparations the mean 
population diameters were 11.8±0.4; 18.0±0.7 and 25.7±1.1 μm, in the proportions 
0.37±0.05; 0.41±0.01 and 0.22±0.05 μm, respectively. Thus, the larger cells were 
significantly less numerous than the other two cell types in these isolated populations. 
These distributions are likely to be determined by the length of trypsin-EDTA 
incubation as the percentage of the larger cell group could be increased for example by  
reducing the incubation time, and therefore cannot be used to assess the relative 
numbers of the different cell types in vivo. Cell viability was confirmed as >80% for all 
isolations used by Trypan blue exclusion: 90.2±0.4% (n=121). Cytokeratin-20 labelled 
95±2% of cells from four sample preparations, indicating their urothelial origin (Figure 
1C). 
 
Comparison of ACh and ATP release: Mechanical stimulation released both ACh and 
for comparison, ATP. ACh release was measured using an Amplex®Red ACh/acetyl 
cholinesterase assay kit (Invitrogen). Figure 2A shows the sensitivity of this assay 
which had a range from about 0.3 to 300 μM. The experiments described here utilised 
the lower end of this curve with maximal ACh release reaching about 20 μM. ACh 
release from 24 tubes from a single experiment is shown in Figure 2B. ACh release can 
be seen to significantly increase following pipetting the solution up and down (pipetting 
action) above that in the absence of stimulation.  Maximal ACh release was achieved 
after a relatively small number of pipetting actions which is shown more clearly in 
Figure 2C which compares the increase in ACh release above baseline from 10 such 
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experiments. This pattern of release differed to that for ATP which was not maximal 
until about 50 pipetting stimuli and was also about two-fold lower than that for ACh 
(Figure 2D). Given the high sensitivity of the ACh release the actual baseline ACh 
release is likely to be smaller than these data imply, as there would be stimulation 
during sampling itself. With ATP release it was estimated that baseline was 
overestimated by about 15% due to sampling stimulation by taking multiple samples 
from the same tube (data not shown). The high sensitivity with ACh prevented this type 
of calculation but we would predict an even larger effect. Comparison of maximal total 
ACh and ATP released without subtraction of baseline values indicates levels of as 
much as five times more ACh than ATP.  
 
Quantification of ACh release: The amount of ACh release following maximal 
stimulation was measured and is plotted in Figure 3A as a function of total cell surface 
area for each individual population. This was calculated using the total cell number and 
percentages of each sub-type of cell in that population and assuming that all the cells 
were spherical. It can be seen clearly that the amount of ACh release increases with the 
total surface area. To determine the amount and range of ACh release more clearly 
these data are presented in Figure 3B as a frequency histogram. The average ACh 
release from these individual calculations was 8.3  0.3 moles-18.μm-2: which is 
equivalent to about 3 μmolesg-1 of cells (assuming a specific density of 1 g cm-3).    
 
To try to discriminate between the release properties of different urothelial cell 
populations, the number of large diameter cells was kept constant at 2.25 x 10
4
 ml
-1
 
whilst total cell density was varied in different samples from a single isolation (see 
methods for details). From the gradient and intercept respectively of linear regressions 
fitted to sets of these data, such as is shown in Figure 3C, ACh production was 
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calculated at  11.7 ± 2.4 moles
-18
.μm-2 (n=6) for the two smaller cell populations and 
7.0 ± 7.7 moles
-18.μm-2 (n=6), for the larger cell population. These values are all well 
within the range shown in Figure 3B suggesting that the three groups of cells all 
contribute a similar amount of ACh release per unit area.  
The effect of calcium on ACh release was investigated in Figure 3D. Addition of 1.8 
mM external calcium had no significant effect on ACh release however; increasing 
intracellular calcium by perfusing the cells with low sodium solution caused a 
significant reduction in ACh release to 43  3% of control (p = 0.0001, n=11). This 
effect was reversed by incubating the cells in BAPTA-AM to chelate the internal 
calcium consistent with it being caused by the rise in intracellular calcium. 
 
 
Pathways involved in ACh release: To study the mechanism of ACh release, cells 
were treated with compounds designed to block different potential release pathways in 
turn. The results are summarised in Figure 4A. Each bar shows the amount of ACh 
release following that treatment expressed as a percentage of its respective paired 
vehicle control. Brefeldin A (BFA) and botulinum toxin (BTX) were both without 
significant effect on stimulated ACh release suggesting a non-vesicular mechanism of 
release. Carbenoxolone (CBX) which blocks connexins and pannexins at the 
concentration used, was also without effect. Organic cation transporters OCT1, OCT2 
and OCT3 have all been demonstrated to be blocked by quinine with IC50 values 
between 0.9 and 14 μM (Koepsell et al., 1998). In the current experiment however, 
quinine at 100 M was without significant effect on ACh release suggesting that an 
OCT is unlikely to be involved. CFTRinh-172, however, an inhibitor of CFTR, which 
has been implicated by some in ATP release (see discussion for references) did have a A
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significant inhibitory effect on ACh release, reducing it to 68 ± 3 % of control 
(p<0.0001, n=20, and see Figure 4C). The IC50 value for this effect was 4.2 ± 0.4 μM 
(Figure 4D).  
For comparison and to test that the drugs themselves were effective when applied to 
isolated cells in the way done here their effects on stimulated ATP release were 
investigated, and presented in a similar way in Figure 4B. Brefeldin A, carbenoxolone 
and CFTR172 all significantly reduced ATP release (Figure 4B). 
 
CFTR immuno-staining was detected in all layers of the urothelium and was highest in 
the outer, umbrella cell layer (Figure 5A). This contrasted with that of CK20 which was 
highest in the basal layer (Figure 5B).  
 
Muscarinic receptor activation and inhibition: To determine whether muscarinic 
receptor activation affects ATP release, the muscarinic agonist carbachol was applied. 
This caused a significant increase in the amount of stimulated ATP release to 137  
11% (p=0.007, n=18) of the control (Figure 6A). Inhibition of muscarinic receptors 
with either 4-DAMP or methoctramine had the opposite affect and reduced ATP release 
to 90  3 % (p=0.03, n=7) and 76  7% (p=0.005, n=12) of the control respectively 
(Figure 6A). Greater inhibition was seen with the M2 selective antagonist 
methoctramine than the M3 selective antagonist 4-DAMP. In the presence of 
methoctramine, carbachol was no longer stimulatory supporting the hypothesis that the 
stimulation by carbachol was via an effect on muscarinic receptors. The pIC50 values for 
inhibition by methoctramine was 6.60 ± 0.25 (n=5) (Figure 6B).  A
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Discussion and conclusions 
This is the first study to measure transmitter release from freshly isolated urothelial 
cells, an approach which complements existing whole tissue and cultured cell 
techniques but represents a more physiological experimental condition. The imposed 
stress used here was reproducible and not harmful, and by producing a large number of 
equivalent tubes of cell suspension, drug application studies and comparisons between 
ACh and ATP were possible in the same populations of cells. Five pipetting stimuli 
were used rather than one to remove any variability between tubes by guaranteeing 
maximal ACh release. The total amount of ACh released equates to about 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
moles g-1 of cells (assuming a specific density of 1 g cm-3 and spherical cells) and is 
considerably higher than that reported elsewhere (Lips et al., 2007; Yoshida et al., 
2004). This is not unexpected for several reasons: the stimulus was maximal; the small 
volumes possible with this technique allow more accurate measurements; the fact that 
the cells are dissociated permits ACh release over their entire surface area; total 
released ACh is measured, as the assay measures choline and so is independent of any 
choline esterase activity that may be present. 
Of significance was the small dynamic range for ACh release. By comparison with ATP 
release it is clear that this is not simply due to the technique but a real difference 
between the two transmitters and suggests a low threshold mechanism for ACh release, 
whereby it is the occurrence of a stretch rather than its magnitude that is communicated. 
Because cholinergic agonists increased ATP release we propose that urothelial ACh 
release acts as a base-line regulator of ATP release, i.e. ACh release alters the gain of 
the graded release of ATP with differing strengths of physical stimuli. Reduction of 
ACh release – e.g. through M2 receptor antagonism – would reduce the sensitivity of 
the stress-mediated release of ATP. 
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We investigated the effects of CFTR172 on ACh and ATP release because CFTR has 
been previously implicated in ATP release in a range of different cell types (Reigada et 
al., 2005) (Jiang et al., 1998; Reisin et al., 1994; Ruan et al., 2012; Schwiebert et al., 
1995), although not in all (Donaldson et al., 2000; Grygorczyk et al., 1997; Hazama et 
al., 1999; Okada et al., 2006; Reddy et al., 1996; Watt et al., 1998). The IC50 value for 
CFTRinh-172 inhibition of ACh release is 10-fold higher than reported in epithelial cells 
(Ma et al., 2002) but similar to 3.5 μM found for ATP inhibition in cultured retinal 
pigment epithelial cells (Reigada et al., 2005). CFTR mRNA has been detected in pig 
bladder tissue by RT-PCR (Plog et al., 2010) and the immunohistochemisty results 
presented here indicate that CFTR protein is expressed within the urothelium. Although 
CFTR has been linked to ATP release in a number of cell types it is unlikely to have 
caused the effects on ACh as both brefeldin A and carbenoxolone reduced ATP without 
affecting ACh release. The selectivity of CFTR for anions over cations is only about 10-
fold (Anderson et al., 1991) and the pore is relatively large (Linsdell et al., 1998) so it is 
possible that ACh could pass directly through the CFTR channel, either alone or with 
some co-factor. It is also possible that CFTR could affect ACh storage and thereby the 
amount available. This is suggested by cystic fibrosis patients who have a 70% reduced 
ACh content in lung tissue and leucocytes (Innis et al., 2011; Wessler et al., 2007) and 
the colocalisation of CFTR and choline acetyltransferase in leucocytes (Wessler et al., 
2007). A role in choline transport is also possible as cystic fibrosis patients have 
reduced plasma choline levels (Innis et al., 2011).  
The absence of an effect of botulinum toxin on non-neuronal ACh release is consistent 
with a non-vesicular pathway and a different mechanism from that for neuronal ACh 
release. It is possible however that botulinum toxin is unable to enter the urothelial cells 
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as botulinum injections have greater efficacy than intravesical application (Smith et al., 
2008) and synaptic vesicle protein SV2 used for internalisation is difficult to identify  in 
urothelial cells (Coelho et al., 2010; Dong et al., 2006) as are cleaved fragments of 
SNAP 25 that represent the target for intracellular botulinum toxin (Coelho et al., 
2012).  
Antimuscarinic drugs are the primary treatment for over-active bladder and were 
introduced as it was presumed that they would antagonise muscarinic receptors on 
detrusor smooth muscle, thus shielding them from excessive release of ACh from 
parasympathetic efferents. Identification of the M3-subtype as the functional muscarinic 
receptor (Chess-Williams et al., 2001) stimulated the manufacture of M3-specific 
antagonists for overactive bladder, such as darifenacin (Haab et al., 2004).  This 
paradigm has been questioned as: anti-muscarinic antagonists seem to be more effective 
during bladder filling (Finney et al., 2006), than emptying, when parasympathetic 
activity would be low; M3-selective agents did not show greater efficacy compared to 
M2/M3 agents (Chapple et al., 2008). These data provide at least a partial explanation 
for these observations: urothelial ACh release occurs during filling via an M2-selective 
pathway and antimuscarinic agents may act on this pathway within the micturition 
cycle. Although both 4-DAMP (M3 selective) and methoctramine (M2 selective) 
reduced ACh release, methoctramine caused the larger reduction. Although the pIC50 
value for inhibition by methoctramine is high compared to its binding constant to the 
M2-receptor, 4-DAMP had little effect even at very high concentrations.  Instead, they 
may both may be acting at M2 receptors but with reduced sensitivity.  
The effect of modulating muscarinic receptors on ATP release suggests that by 
inhibiting ACh release, CFTRinh-172 could reduce ATP release indirectly, although a A
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direct route cannot be ruled out. Either way, inhibition of CFTR offers an exciting new 
target for the treatment of over-active bladder.  
In conclusion, pressure on isolated urothelial cells caused ACh release from urothelial 
cells by a route different from that for ATP and involving CFTR.  It is hypothesised that 
this ACh may control ATP release and thus contributes to the action of antimuscarinic 
agents to reduce symptoms of LUTS through attenuation of sensory afferent pathways. 
Additionally, the identification of an involvement of CFTR in ACh release offers the 
exciting new possibility of targeting CFTR, possibility as part of a multi-drug approach, 
in the treatment of lower urinary tract disorders. 
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Figure legends 
Figure 1: The population of isolated urothelial cells. (A) Isolated urothelial cells as 
viewed to count and differentiate sub-populations, bar is 50 μm. (B) Frequency 
distribution of cell diameters of 2399 cells from 5 populations fitted with three 
Gaussians distributions (see methods). Envelope shows the sum of these three fits. (C) 
Cells labelled with anti-KRT 20 antibody to show urothelial origin, bar is 20 μm 
Figure 2: Urothelial cells release ACh and ATP. (A) Standard curve for the ACh assay 
showing the dynamic range (approx 0.3 – 300 μM). (B) ACh release from 24 tubes 
from the same population subjected to 0 – 10 pipetting actions to show intra-experiment 
variability. There are four points for each treatment but some are obscured by each 
other. (C) ACh produced, above that in the absence of stimulation, one minute after; 
dipping a 200 μl pipette tip into the tube without sucking (x0.5) or pipetting 20 μl up 
and down between 1 and 50 times as shown. (n=10). Release was significantly 
increased above the non-stimulated value with 1 or more pipetting actions. (D) ATP 
release from the same populations of cells as in (C) treated in the same way to a 
maximum of 100 pipetting actions. 
Figure 3: ACh release as a function of cell density. (A) ACh release as a function of 
total membrane surface area in 45 l of cell suspension from different populations. All 
populations were a mixture of the three cell groups in varying proportions. Surface area 
was calculated assuming cells were spherical with diameters from the fits in Figure 1B 
as given in the text. (B) Same data as in (A) but plotted as a frequency histogram of the 
ACh release per unit square micrometer of surface area in the tube. (C) ACh production 
as a function of the membrane area of the two smaller populations of cells (basal and 
intermediate) from a single isolation with constant larger (umbrella) cell number A
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(2.25x10
4 
ml
-1
) but varying total cell number. (D) Stimulated ACh as a percentage of its 
own paired Tyrode’s control with no added external calcium. The bars show 
respectively, Tyrodes with 1.8 mM extracellular calcium added (no significant effect on 
ACh release), low sodium Tyrode’s which has been shown to increase intracellular 
calcium (ACh release was significantly reduced to 43  3% of the control p=0.0001, 
n=11) and this low sodium Tyrode’s with BAPTA-AM which reversed the effect of the 
low sodium treatment (not significantly different to Tyrode’s control, n=6).   
Figure 4: Analysis of the mechanism of ACh release. (A) Effect of brefeldin-A (BFA, 
10
-5 
g/ml, 95% confidence interval 88-138%, n=14, NS), Botulinum-A toxin (BTX, 4U 
or 10U, 95% confidence interval 96-121%, n=7, NS), carbenoxolone (CBX, 5x10
-4 
M, 
95% confidence interval 88-113%, n=6, NS), Quinine (Q, 10
-4
M, 95% confidence 
interval 81-110%, n=12, NS) and CFTRinh-172 (CFTR172, 3x10
-5 
M, to 68  4% 
p<0.0001, n=20) on ACh production as a percentage of their appropriate control. (B) 
Corresponding data for ATP release with the same drug concentrations, illustrating a 
significant decrease in ATP release with brefeldin A (to 73  6% of control (n=12, 
p=0.015)), carbenoxolone (to 71  7% of control, n=13, p=0.0074) and CFTRinh172 (to 
60  11% of control, n=8, p=0.004). (C) Paired control (DMSO) and CFTRinh172 
treated populations showing the decrease in stimulated ACh on application of CFTRinh 
172 in more detail. (D) Dose-response curve for inhibition of ACh production by 
CFTRinh-172. (IC50 value = 4.2 ± 0.4 x10
-6 
M).  
Figure 5:  Distribution of CFTR and Cytokeratin-20 labelling in the bladder 
urothelium. (A) Staining with anti-CFTR antibody, showing greatest labelling in the 
outer, umbrella cell layer. Arrow indicates lamina propria, barrier between the 
urothelium and suburothelium. (B) Similar section labelled with Anti-KRT20, showing 
highest labelling in the basal cell layer. Bars are 25 μm. 
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Figure 6: Muscarinic receptor activation affects ATP release. (A) ATP release 
following shear stress x50, in the presence of carbachol (Carb, 10
-5
M, to 137  11 5 
control, p=0.007, n=18, one outlier was omitted as ATP release was much greater than 
the rest), 4-DAMP (5x10
-7
M, to 90  3% of control, p=0.026, n=7), methoctramine 
(Methoc, 10
-5
 M, to 76  7% control, p=0.005, n=12) and methoctramine and carbachol 
(methoc + carb, 68  9%, n=5), each expressed as a percentage of the corresponding 
control. (B) Dose-dependent inhibition of ATP release by methoctramine, expressed as 
a percentage of DMSO control in the absence of drug. 
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Appendix:  Estimation of the drag force on an isolated cell. 
The following is not intended to be an exact calculation of the force imposed on an isolated 
cell during a pipetting action but an estimate to determine if it is similar to a physiological 
force per unit area on the bladder wall during filling.  Normal transmural bladder pressure 
during filling increases from approximately 0 to 10 cm H2O (Schafer et al., 2002). The 
estimation involves calculating the drag force (F, Stoke’s Law) on a submerged particle.  The 
value of F on a unit cross-sectional area of a spherical particle is: 
  
  
F
A
=
Cdrv
2
2
 
Where, Cd is the drag coefficient,  the density of suspending fluid, A the cell cross-section 
area (=r2), r the cell radius and v the relative velocity of the cell relative to that of the 
suspending fluid.  Cd, is calculated from the particle Reynold’s number, Rp=24/Cd 
  
  
Rp = r.v.r / m 
Where,  is the viscosity of the suspending fluid. Thus,  
  
  
F
A
=
6mv
r
 
Let r = 20 µm and  ≈ 10-3 Pa.s (viscosity of water at room temperature).  To calculate v: 20 
µl was pipetted through a ‘yellow tip’ of smallest diameter 0.5 mm (Brand™, Germany) and 
v will be greatest at the narrowest region.  Each pipetting action lasted 0.6 seconds as 50 
actions were completed in 30 seconds, thus one upward movement lasted 0.3 seconds. 
Flow velocity, v = 
  
  
volume pipetted (m3)
pipette area (m2 )* 0.3 s
=
2.10-8
p.2.52.10-8 * 0.3
= 0.34m.s-1 
 
Thus, drag force per unit area, F/A, per pipetting action is = 
  
  
6.10-3.0.34
2.10-5
»100 Pa » 0.1 kPa 
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A limitation of the calculation is that v is calculated as the mass fluid velocity and the relative 
velocity of cell to suspension medium will be less.  The value of F/A will therefore be an 
upper limit. 
 
As 0.1 kPa ≈ 1 cm H2O this represents the drag force per unit area on a cell for every 
pipetting movement.  This pressure is similar to transmural bladder pressure during filling 
and the experimental manoeuvre therefore represents a physiological stimulus. 
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